Possible scenario
Option Value Deal
45% Chance
The most likely outcome is that Novo Nordisk treats Nanexa's depot-delivery technology as a strategic option rather than an immediate replacement for Wegovy. The deal helps Novo signal that it is responding to Eli Lilly and Viking Therapeutics on injection burden, but clinical proof and manufacturing scale remain years away.
Tickers
- VKTX-1.1%
- LLY-0.6%
Portfolio impact
S&P 500-0.0%
Each figure is the modeled move of the S&P 500 if the outcome occurs. For information only. Not investment advice.
Keeping an eye on this scenario?
Tilt can alert you when its probability or impact shifts, or send you a recommendation when it crosses a threshold.